Abstract:Poly(lactide- co -glycolide) and poly(lactic-co-glycolic acids) (PLGAs) play a critical role in the development of commercial long-acting injectable microsphere formulations. However, very little information is available describing the impact of PLGA manufacturer and monomer distribution along the polymer chain (e.g, glycolic blockiness (R c ) and average lactic block length (L L )) on the degradation and release behavior of PLGA drug carriers in vitro and in vivo. Here, we compared the in vitro and in vivo performance of ( a ) four leuprolide-loaded microsphere formulations prepared from similar low-molecular-weight acid-capped PLGAs (10–14 kD, i.e, Expansorb ® DLG 75-2A, Purasorb ® PDLG 7502A, Resomer ® RG 752H and Wako ® 7515) and ( b ) two triamcinolone acetonide-loaded (Tr-A) microsphere formulations from similar medium-molecular-weight ester-capped PLGAs ( i.e. , Expansorb ® DLG 75-4E and Resomer ® RG 753S). Lupron Depot ® and Zilretta ® were used as reference commercial products. The six 75/25 PLGAs displayed block lengths that were either above or below values expected from a random copolymer. Drug release and polymer degradation were monitored simultaneously in vitro and in vivo using a cage implant system. The four leuprolide-loaded formulations showed similar release and degradation patterns with some notable differences between each other. Microspheres from the Expansorb ® polymer displayed lower L L and higher R c relative to the other 3 PLGA 75/25 microspheres, and likewise exhibited distinct peptide release and degradation behavior compared to the other 3 formulations. For each formulation, leuprolide release was erosion-controlled up to about 30% release after the initial burst followed by a faster than erosion release phase. In vitro release was similar as that in vivo over the first phase but notably different from the latter release phase, particularly for the most blocky Expansorb ® formulation. The Purasorb ® and Wako ® formulations displayed highly similar performance in release, degradation, and erosion analysis. By contrast, the two ester-capped Expansorb ® DLG 75-4E and Resomer ® RG 753S used to prepare Tr-A microspheres shared essentially identical L L and higher R c and behaved similarly although the Expansorb ® degraded and released the steroid faster in vivo, suggestive of other factors responsible (e.g., residual monomer). The in vivo release performance for both drugs from the six microsphere formulations was similar to that of the commercial reference products. In summary, this work details information on comparing the similarities and differences in in vitro and in vivo performance of drug-loaded microspheres as a function of manufacturing and microstructural variables of different types of PLGA raw materials utilized and could, therefore, be meaningful in guiding the source control during development and manufacturing of PLGA microsphere-based drug products. Future work will expand the analysis to include a broader range of L L and higher R c , and add additional important formulation metrics (e.g., thermal analysis, and residual monomer, moisture, and organic solvent levels).

Key Factor Study for Generic Long-Acting PLGA Microspheres Based on a Reverse Engineering of Vivitrol®

Bridging the gap between fundamental research and product development of long acting injectable PLGA microspheres

In Vitro and in Vivo Evaluations of PLGA Microspheres Containing Nalmefene

Optimizing Process Parameters for Controlled Drug Delivery: A Quality by Design (QbD) Approach in Naltrexone Microspheres

Formation Mechanism and in Vitro Evaluation of Risperidone-Containing PLGA Microspheres Fabricated by Ultrafine Particle Processing System.

Modified Preparation Method and Characteristics of Nimodipine-Loaded PLGA Microspheres

Preparation of uniform-sized GeXIVA[1,2]-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency

Studying spatial drug distribution in golf ball-shaped microspheres to understand drug release

Implications of particle size on the respective solid-state properties of naltrexone in PLGA microparticles

Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres.

The Preparation of NC-PLGA Microspheres and Experimental Study in Vivo and Vitro on the Pharmacokinetics

Development of Andrographolide Loaded PLGA Microspheres: Optimization, Characterization and in Vitro–in Vivo Correlation

Formulation Optimization and in Vitro Characterization of Granisetronloaded Polylactic-co-glycolic Acid Microspheres Prepared by a Dropping-in-liquid Emulsification Technique.

Thermosensitive Hydrogel Incorporating Microspheres for Injectable Implant Delivery of Naltrexone

Preparation, Characterization and in Vitro Evaluation of IVM Loaded Poly(lactic-Co-Glycolic Acid) (PLGA) Microspheres

PLGA sustained-release microspheres loaded with an insoluble small-molecule drug: microfluidic-based preparation, optimization, characterization, and evaluation in vitro and in vivo

Preparation and in vitro evaluation of risperidone loaded PLGA microspheres

Microfluidic preparation of monodisperse PLGA-PEG/PLGA microspheres with controllable morphology for drug release.

Effect of PLGA raw materials on in vitro and in vivo performance of drug-loaded microspheres

A Novel Accelerated in Vitro Release Method to Evaluate the Release of Thymopentin from PLGA Microspheres.

Improvement of liraglutide release from PLGA microspheres by a porous microsphere-gel composite system